Trimedoxime bromide

{{Short description|Chemical compound}}

{{Drugbox

| IUPAC_name = 1,1{{prime}}-propane-1,3-diylbis{4-[(E)-(hydroxyimino)methyl]pyridinium} dibromide

| image = Trimedoxime bromide structure.svg

| width = 250

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status = Experimental; in military use

| routes_of_administration = Intramuscular injection

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life = 2 hours (mean)

| excretion =

| CAS_number = 56-97-3

| ATC_prefix = None

| ATC_suffix =

| PubChem = 5359236

| DrugBank =

| ChemSpiderID = 4514238

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = ED0GXI9825

| C=15 | H=18 | N=4 | O=2 | Br=2

}}

Trimedoxime bromide (INN), also known as dipyroxime or TMB-4, is an oxime used in the treatment of organophosphate poisoning{{cite journal | vauthors = Dhuguru J, Zviagin E, Skouta R | title = FDA-Approved Oximes and Their Significance in Medicinal Chemistry | journal = Pharmaceuticals | location = Basel, Switzerland | volume = 15 | issue = 1 | date = January 2022 | page = 66 | pmid = 35056123 | pmc = 8779982 | doi = 10.3390/ph15010066 | doi-access = free }} It is chemically related to asoxime, pralidoxime, and obidoxime.{{cite book | vauthors = Gupta R, Parmar M | chapter = Pralidoxime |title=StatPearls |date=2022 | location = Treasure Island (FL) |publisher=StatPearls Publishing | pmid = 32644334 | chapter-url= https://www.ncbi.nlm.nih.gov/books/NBK558908/ }}